Cormorant Asset Management PCVX Position
Active14-Fund ConvergenceCormorant Asset Management trimmed their position in Vaxcyte Inc. (PCVX) in Q4 2025, holding $5.8M worth of shares across 125,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
PCVX is a convergence signal: 14 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for 31 valent pneumococcal conjugate vaccine in 292 days (Jan 31, 2027), making the timing of Cormorant's position particularly relevant.
Short interest stands at 10.1% of float with 10.6 days to cover, indicating significant bearish positioning against Cormorant's long thesis.
About Vaxcyte Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Full company profile →Short Interest
10.1%
10.6 days to cover
Cormorant Asset Management PCVX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 125,000 | -50,000 | $5.8M |
| Q3 2025 | Held | 175,000 | — | $6.3M |
| Q2 2025 | Held | 175,000 | — | $5.7M |
| Q1 2025 | Decreased | 175,000 | -250,000 | $6.6M |
| Q4 2024 | Decreased | 425,000 | -575,000 | $34.8M |
| Q3 2024 | Decreased | 1,000,000 | -100,000 | $114.3M |
| Q2 2024 | Increased | 1,100,000 | +415,000 | $83.1M |
| Q1 2024 | Increased | 685,000 | +20,000 | $46.8M |
| Q4 2023 | Held | 665,000 | — | $41.8M |
| Q3 2023 | Held | 665,000 | — | $33.9M |
| Q2 2023 | Increased | 665,000 | +390,000 | $33.2M |
| Q1 2023 | New | 275,000 | +275,000 | $10.3M |
Frequently Asked Questions
Does Cormorant Asset Management own PCVX?
Yes. As of Q4 2025, Cormorant Asset Management holds 125,000 shares of Vaxcyte Inc. (PCVX) valued at $5.8M. This data comes from their SEC 13F filing.
How many hedge funds own PCVX?
14 specialist biotech hedge funds currently hold PCVX, including RA Capital Management, Perceptive Advisors, Driehaus Capital and 10 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy PCVX?
Cormorant Asset Management's position in PCVX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's PCVX position increasing or decreasing?
Cormorant Asset Management trimmed their PCVX position in the most recent quarter, reducing by 50,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PCVXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →